Family History of Breast Cancer, BRCA, and Cosmetic Breast Surgery: Who Should Have Genetic Testing First, How Implants and Lifts Change Screening, What Atypia and Tamoxifen Mean for Timing, and How to Plan Around a Possible Risk-Reducing Mastectomy

The patient is 34. She has two children, she is finished breastfeeding, and she would like her breasts back: a lift, with small implants to restore the volume that pregnancy took. On the intake form, under family history, she wrote that her mother was diagnosed with breast cancer at 44 and that her mother's sister died of ovarian cancer in her fifties. Nobody in the family has had genetic testing. Her mother, now in her sixties and well, was treated before testing was routine and never went back to ask.

She would like to know whether any of that matters for a breast lift. It matters more than for almost any other cosmetic operation, and not for the reason most patients assume. A breast augmentation or lift does not raise her risk of breast cancer. What her family history raises is the probability that she carries an inherited variant in a gene such as BRCA1 or BRCA2, and if she does, the next decade of her breast care may include intensive MRI screening and, possibly, a risk-reducing mastectomy. A cosmetic breast operation planned without knowing that can be the wrong operation, at the wrong time, with scars in the wrong place.

This piece covers whether cosmetic breast surgery changes cancer risk, who should have a formal risk assessment and genetic counseling before booking, how implants, lifts, reductions, and fat grafting affect breast imaging, what a biopsy showing atypia or LCIS and a prescription for tamoxifen mean for elective surgery, and how a known carrier can plan cosmetic breast surgery around a mastectomy they may or may not choose.

Does breast augmentation, a lift, or a reduction change breast cancer risk?

The short answer: no credible evidence shows that breast implants, lifts, or fat grafting cause breast cancer, and large cohort studies suggest that breast reduction may modestly lower the risk, but none of these operations is a risk-reduction strategy for a woman with an inherited predisposition, and the real interaction between cosmetic breast surgery and breast cancer is about screening and planning, not causation.

The question of whether implants cause breast cancer was investigated exhaustively in the 1990s, during the silicone controversy. The Institute of Medicine's 1999 review of the evidence found no link between breast implants and breast cancer, and the epidemiological studies since then, including long-term cohorts of augmented women in Scandinavia and North America, have reached the same conclusion. The FDA's current labeling for breast implants addresses breast implant associated anaplastic large cell lymphoma, a rare lymphoma of the scar capsule linked predominantly to textured devices and covered in the piece on the BIA-ALCL risk picture, and that is a separate disease from breast cancer, arising in the capsule rather than the breast tissue.

Breast reduction is the one cosmetic breast operation with a plausible protective effect, and the mechanism is simple: it removes breast tissue, and less glandular tissue means fewer cells that could become malignant. Large Scandinavian cohort studies of women who had reduction mammaplasty found lower breast cancer rates than expected, with the reduction roughly proportional to the amount of tissue removed. That is a reassuring footnote for a patient considering the operation described in the piece on breast reduction surgery. It is not a reason for a BRCA carrier to choose a reduction instead of the risk-reducing operations discussed below, because a reduction leaves most of the glandular tissue behind, and for a carrier the remaining tissue still carries a very high lifetime risk.

Fat transfer to the breast generated more concern when it was introduced, largely because fat necrosis and oil cysts can produce calcifications on mammography, and because fat grafts carry stem cells and growth factors that raised theoretical questions about stimulating dormant cancer cells. The American Society of Plastic Surgeons' fat grafting task force concluded in 2009 that the procedure could be considered with appropriate caution, and the studies published since have not shown an increase in breast cancer among women who had fat grafting. The practical caveats are imaging ones, discussed below, and the pieces on fat transfer breast augmentation and fat necrosis after fat transfer cover what those lumps look like.

The point of separating causation from planning is that patients with a family history often arrive with the wrong worry. They fear that implants might give them cancer, which is not supported. They do not think to ask whether implants will make their cancer harder to find, whether their family history warrants testing before the operation rather than after, or whether a mastectomy in five years would make today's lift a wasted operation. Those are the questions this piece is about.

Who should have a risk assessment and genetic counseling before cosmetic breast surgery

The short answer: anyone with a close relative diagnosed with breast cancer at 50 or younger, ovarian cancer at any age, male breast cancer, triple-negative breast cancer, pancreatic cancer, or a known familial gene variant, and anyone of Ashkenazi Jewish ancestry with any of these in the family, should have a formal risk assessment and, where it points that way, genetic counseling and testing before elective breast surgery, not after.

In the general population, a woman's lifetime risk of breast cancer is about 13 percent, roughly one in eight, according to the National Cancer Institute. For women who inherit a harmful variant in BRCA1, the National Cancer Institute cites estimates of about 55 to 72 percent by age 70 to 80, and for BRCA2, about 45 to 69 percent. Both genes also raise the risk of ovarian cancer substantially. Other genes matter as well: PALB2 carries a risk approaching that of BRCA2, and variants in CHEK2, ATM, TP53 (the cause of Li-Fraumeni syndrome), PTEN (Cowden syndrome), and CDH1 raise breast cancer risk to differing degrees. Modern genetic testing usually examines a panel of these genes at once.

The features in a family history that should prompt a referral are well established, and versions of them appear in the guidelines from the National Comprehensive Cancer Network and the US Preventive Services Task Force, which recommends that primary care clinicians assess women with a personal or family history suggestive of an inherited variant and refer those who screen positive for genetic counseling. The common red flags:

• Breast cancer diagnosed at 50 or younger in a mother, sister, daughter, aunt, or grandmother, on either side of the family. The father's side counts as much as the mother's, a fact many patients do not realize.
• Ovarian, fallopian tube, or primary peritoneal cancer in any relative, at any age.
• Male breast cancer in any relative.
• Triple-negative breast cancer, especially when diagnosed at 60 or younger.
• Two or more relatives on the same side with breast cancer, or one relative with cancer in both breasts.
• Pancreatic cancer or metastatic prostate cancer in the family, which are also associated with BRCA2 and related genes.
• Ashkenazi Jewish ancestry, in which roughly one in 40 people carries one of three founder variants in BRCA1 or BRCA2, a rate many times higher than in the general population.
• A known harmful variant already identified in a relative.

The American College of Radiology now recommends that every woman have a formal breast cancer risk assessment by age 25, partly so that women at high risk can start screening early. A cosmetic breast consultation is, for many women in their twenties and thirties, the first time a physician has looked carefully at their breasts as an adult, and a careful surgeon treats the family history question as clinically meaningful rather than as a box on a form. The piece on age limits for cosmetic surgery notes how often consultations are the first real medical contact for young, healthy patients.

Several practical points come up repeatedly:

Consumer DNA tests are not genetic testing for this purpose. The direct-to-consumer test that the FDA authorized in 2018 to report BRCA results looks at only three variants, the Ashkenazi founder variants, out of thousands of known harmful variants in those two genes. A negative consumer test in a woman whose mother had breast cancer at 44 is not reassurance. A clinical panel ordered through a genetic counselor or physician is the appropriate test.

Testing the affected relative first is often more informative. If the mother is alive and willing, testing her first can identify the specific variant in the family, which makes the daughter's result far easier to interpret. A negative result in the daughter means much more when the family variant is known.

Timing matters. Genetic counseling appointments can take weeks to schedule, results usually take two to three weeks, and a positive result can open a cascade of imaging and specialist visits. Booking surgery for next month and testing afterward puts the decision in the wrong order.

Genetic discrimination protection is partial. The federal Genetic Information Nondiscrimination Act of 2008 prohibits the use of genetic information in health insurance and employment decisions, but it does not cover life insurance, disability insurance, or long-term care insurance. Some patients choose to arrange those policies before testing. That is a legitimate consideration and worth knowing about before the blood draw, not after.

Men are not exempt. A man with a BRCA2 variant has a lifetime risk of male breast cancer that is still low in absolute terms but far above the general male risk, which is well under one percent. Men having gynecomastia surgery with a strong family history of BRCA-associated cancers, or with a known family variant, should mention it, and the tissue removed, as described in the piece on gynecomastia surgery, goes to pathology for good reason.

Screening with implants, after a lift or reduction, and after fat grafting

The short answer: implants partly obscure breast tissue on mammography, which is managed with displacement views and, for high-risk women, MRI; lifts, reductions, and fat grafting create scars and calcifications that radiologists can usually distinguish from cancer when they have baseline images and an accurate surgical history; and the high-risk woman's MRI is a different scan from the implant rupture MRI.

Baseline imaging before surgery. Many plastic surgeons ask women over about 35 or 40, or younger women at elevated risk, to have a mammogram within the year before breast surgery. Two reasons: to avoid operating on a breast that contains an undiagnosed cancer, and to create a baseline against which postoperative changes can be compared. For a high-risk woman, the pre-operative imaging may include an MRI as well. The pieces on fibroadenoma and benign breast lumps and breast imaging after implants and fat transfer explain what happens when that baseline finds something.

Implants and mammography. An implant is opaque to X-rays and sits either behind or in front of the chest muscle. Radiologists use implant displacement views, a technique described by Eklund in the late 1980s, in which the implant is pushed back against the chest wall and the breast tissue pulled forward and compressed in front of it. Even with these views, some tissue is not fully seen, and implants placed above the muscle obscure more than those placed beneath it. A 2013 meta-analysis in the BMJ raised the question of whether augmented women were diagnosed at a later stage, though the quality of the underlying studies was limited and the finding remains debated. For an average-risk woman, the practical response is to tell every mammography facility about the implants so that the appropriate views are taken. For a high-risk woman, the answer is MRI, which sees breast tissue regardless of the implant. The placement question, discussed in the piece on pre-pectoral breast implant placement, is worth raising with this in mind.

Two different MRIs. A woman with silicone implants may have heard that the FDA recommends periodic imaging to check for silent rupture, as covered in the piece on long-term breast implant surveillance. That scan, which can be done without contrast, looks at the implant. The screening MRI recommended for women at high risk of breast cancer uses an intravenous gadolinium contrast agent and is designed to find cancer in the breast tissue. They are not interchangeable, and a high-risk woman with implants needs the cancer protocol; the radiologist can assess the implant during the same study.

MRI for high-risk women. The American College of Radiology and the National Comprehensive Cancer Network recommend annual breast MRI, in addition to mammography, for women with a lifetime risk of about 20 percent or higher by standard risk models, and for carriers of BRCA1, BRCA2, and several other variants. For BRCA carriers, guidelines generally recommend starting MRI around age 25, adding annual mammography at 30. That screening schedule continues with or without implants.

Lifts, reductions, and scars. A breast lift or reduction rearranges tissue and leaves internal scarring, and fat necrosis from the operation can produce lumps and calcifications on later imaging. Radiologists see these changes routinely and can usually recognize them as benign, especially with prior images available, but an occasional finding leads to a biopsy that would not otherwise have been needed. Patients should keep a written record of the operation, the date, and the incision pattern, as described in the piece on breast lift incision patterns, and give it to every imaging facility.

Dense breasts. Since September 2024, an FDA rule under the Mammography Quality Standards Act has required mammography facilities nationwide to tell patients whether their breasts are dense. Dense tissue both makes mammography less sensitive and is itself a modest risk factor. A woman with dense breasts and a strong family history is a candidate for a formal risk calculation and, often, supplemental imaging.

"A breast lift does not give anyone cancer. The question a family history raises is whether the lift is the right operation to have this year, and nobody can answer it until the genetic counselor has."

Atypia, LCIS, and tamoxifen: what a high-risk biopsy result means for elective breast surgery

The short answer: atypical ductal or lobular hyperplasia and lobular carcinoma in situ are not cancer but substantially raise future breast cancer risk, which usually means enhanced screening and an offer of risk-reducing medication, and those medications, particularly tamoxifen and raloxifene, increase the risk of blood clots, so they often need to be paused around a major elective operation in coordination with the prescribing physician.

Some women arrive at a cosmetic consultation with no inherited variant but with a biopsy result that has placed them in a high-risk category. The most common are:

• Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH), in which cells lining the ducts or lobules look abnormal but do not meet the criteria for cancer. A 2015 review in the New England Journal of Medicine from the Mayo Clinic benign breast disease group reported a cumulative breast cancer incidence approaching 30 percent at 25 years after a diagnosis of atypical hyperplasia, several times the risk of the general population.
• Lobular carcinoma in situ (LCIS), which despite its name is generally treated as a marker of increased risk rather than a cancer requiring removal, and which raises the risk of breast cancer in both breasts by a similar order of magnitude.

These diagnoses often lead to surgical excision of the biopsied area to make sure nothing more serious is present nearby, followed by enhanced screening, frequently including MRI, and an offer of risk-reducing medication. The evidence for that medication is strong. In the large NSABP P-1 prevention trial, tamoxifen roughly halved the incidence of invasive breast cancer in high-risk women, with an even larger reduction among those with atypical hyperplasia. Raloxifene, tested against tamoxifen in the STAR trial, is an option for postmenopausal women, and the aromatase inhibitors anastrozole and exemestane have shown risk reduction in postmenopausal women as well. The US Preventive Services Task Force recommends that clinicians offer these medications to women at increased risk who are at low risk of adverse effects.

For a cosmetic surgeon, these medications raise two issues.

Blood clots. Tamoxifen and raloxifene increase the risk of deep vein thrombosis and pulmonary embolism, the same mechanism, through estrogen receptor effects on clotting factors, that the piece on birth control before cosmetic surgery describes for estrogen-containing pills. A major elective operation adds its own clot risk, and the two compound, as covered in the piece on blood clots after plastic surgery. Many plastic surgeons ask that tamoxifen or raloxifene be paused for a period before a significant elective operation and restarted once the patient is fully mobile. The evidence on the ideal interval is thin, and the decision belongs jointly to the surgeon and the oncologist or breast specialist who prescribed the drug. A short interruption in a five-year preventive course is generally considered acceptable. The aromatase inhibitors do not carry the same clot risk, but they cause bone loss and joint aches, and a patient on them may already be under bone density monitoring, a topic addressed in the piece on osteoporosis and cosmetic surgery.

Timing relative to surveillance and surgery. A woman with atypia or LCIS is usually on a screening schedule, and her elective surgery should fit around it: imaging completed and clear before the operation, and the next scheduled MRI timed with enough postoperative healing that inflammatory changes do not complicate interpretation. Radiologists typically prefer to wait several months after breast surgery before a screening MRI, because early postoperative enhancement can mimic disease. A cosmetic operation booked two weeks before the annual MRI creates exactly the kind of ambiguous scan that leads to unnecessary biopsies.

A small number of women with atypia or LCIS and other risk factors consider risk-reducing mastectomy. Most do not, and current guidelines generally do not recommend it for atypia alone. But a woman who is weighing it should do so before a cosmetic breast operation, not after.

Known BRCA carriers: cosmetic breast surgery now, or planning around a risk-reducing mastectomy

The short answer: carriers can have cosmetic breast surgery, and many do, but the operation should be chosen with a possible future mastectomy in mind, because implant placement, lift and reduction scars, and the blood supply to the nipple all affect what a later nipple-sparing mastectomy and reconstruction can achieve, and for some carriers it makes more sense to combine the cosmetic goal with the risk-reducing operation than to do them years apart.

Risk-reducing mastectomy lowers the risk of breast cancer in BRCA carriers by about 90 percent or more. It is a choice, not a requirement: many carriers opt for intensive surveillance with annual MRI and mammography instead, at least for a period, often until they have finished having children. Carriers are also generally advised to have their ovaries and fallopian tubes removed, around age 35 to 40 for BRCA1 and somewhat later for BRCA2, once childbearing is complete, because effective ovarian cancer screening does not exist. That operation causes immediate menopause, with consequences for skin, bone, and body composition that some patients find relevant to their cosmetic plans.

Each cosmetic breast operation interacts with a possible future mastectomy differently.

Augmentation. A carrier who has an augmentation and later a mastectomy will lose the breast tissue and keep, or exchange, the implant. A prior augmentation can make reconstruction easier in some respects, because the skin has already been expanded and the patient is accustomed to implants, and harder in others, because the mastectomy skin flaps over an existing implant pocket can be thin. Placement matters: an implant beneath the muscle and one above it lead to different reconstruction options. The piece on breast reconstruction after mastectomy covers the reconstruction choices themselves. A carrier planning an augmentation should know that the implants are likely to be revised or replaced during a later mastectomy, and that the fold incision commonly used for augmentation, discussed in the piece on breast augmentation incision choice, is also a common access route for nipple-sparing mastectomy, which is a point in its favor for carriers.

Lifts and reductions. Nipple-sparing mastectomy preserves the nipple and areola, and its success depends on the blood supply that reaches the nipple through the remaining skin. A lift or reduction divides some of that blood supply and leaves scars around the areola and on the lower breast. A later nipple-sparing mastectomy after a prior lift or reduction is possible, and surgeons do perform them, but the risk of nipple necrosis is higher and the mastectomy incision has to work around the existing scars. For women with large or ptotic breasts who are planning a mastectomy, surgeons sometimes stage the operations on purpose: a reduction or lift first, then the nipple-sparing mastectomy months later, once the nipple's blood supply has adapted to its new position. That staged sequence is very different from a cosmetic lift done today with no thought of a later mastectomy, and the difference is in the planning, not the technique.

Combining operations. A carrier who has decided on a risk-reducing mastectomy, and who also wants larger, smaller, or lifted breasts, is often better served by having her cosmetic goals addressed within the reconstruction than by having a cosmetic operation first. The Women's Health and Cancer Rights Act of 1998 requires group health plans that cover mastectomy to cover reconstruction and procedures on the other breast to achieve symmetry, which means that a reconstruction can, in practice, include changes in size and shape the patient wanted anyway. A cosmetic operation done a year before the mastectomy is paid for out of pocket and may be partly undone.

Breastfeeding and family planning. Many carriers in their twenties and thirties have not finished having children. Breastfeeding after augmentation is often possible, and after reduction sometimes, as covered in the piece on breastfeeding after breast surgery, but a risk-reducing mastectomy ends it. A carrier choosing between a lift now, a lift after her last pregnancy, and a mastectomy after her last pregnancy is making a decision about the next decade, and it deserves a conversation with a breast surgeon or high-risk clinic as well as a plastic surgeon. A second consultation with a surgeon who performs both reconstruction and cosmetic breast surgery is often the most useful one.

Reduction specimens and incidental findings. When breast tissue is removed in a reduction, it goes to pathology, and occasionally that tissue contains atypia or, rarely, an unsuspected cancer. The piece on the pathology report after cosmetic surgery covers how often that happens and what follows. For a woman with a strong family history, the report from a reduction is not a formality: she should ask to see it, keep a copy, and give it to her breast specialist.

None of this means a carrier must avoid cosmetic breast surgery. It means the surgeon should know her genetic status, her screening plan, and her thinking about mastectomy before recommending an operation, and that some carriers, having heard the full picture, choose to wait.

The honest summary

Cosmetic breast surgery does not cause breast cancer. Implants have been studied for three decades without a link to breast cancer, reductions may modestly lower risk, and fat grafting has not been shown to raise it. What cosmetic breast surgery does is change the conditions under which breast cancer is screened for and, for women at high risk, the options available if they later choose a mastectomy.

A family history of early breast cancer, ovarian cancer at any age, male breast cancer, or Ashkenazi Jewish ancestry with cancer in the family is a reason for formal risk assessment and genetic counseling before elective breast surgery, not after. A consumer DNA test is not a substitute. Testing an affected relative first is often more useful. Results take weeks, and the federal genetic nondiscrimination law does not cover life, disability, or long-term care insurance.

Implants obscure part of the breast on mammography, which is managed with displacement views and, for high-risk women, annual contrast MRI, a different scan from the implant rupture check. Lifts, reductions, and fat grafting leave scars and calcifications that radiologists can usually interpret correctly when they have baseline images and an accurate surgical history. Elective surgery should be timed around a high-risk woman's screening schedule, not on top of it.

Atypia and LCIS raise future risk and often lead to tamoxifen, raloxifene, or an aromatase inhibitor. The first two raise clot risk, and pausing them around a major operation is a joint decision between the surgeon and the prescriber. For BRCA carriers, augmentation placement, lift and reduction scars, and the nipple's blood supply all affect a later nipple-sparing mastectomy, and for some carriers, folding the cosmetic goal into a risk-reducing mastectomy and reconstruction makes more sense than doing two separate operations years apart.

The patient at the top of this piece did not book a lift at her first consultation. Her mother agreed to genetic testing, which found a BRCA2 variant, and the patient tested positive for the same variant three weeks later. She started annual MRI and mammography, met with a high-risk breast clinic, and decided she wanted one more child before considering a mastectomy. The lift was postponed. She said afterward that she had come in for a cosmetic consultation and left with a screening plan she had not known she needed, and that her aunt's ovarian cancer, a line on a form she had nearly left blank, turned out to be the most important thing she wrote down.